Key Points
- Equillium COO Christine Zedelmayer sold 185,937 shares on Feb 19 at an average price of $1.76 for about $327,249, cutting her direct ownership by 49.27% to 191,444 shares.
- She has made several recent insider sales (another 143,802 shares sold in Nov–Dec for roughly $205,179), bringing total recent insider sales to about 329,739 shares.
- Equillium shares opened at $1.85 (up 6.3%), the company has a market cap of ~$112.6M and a 52‑week range of $0.27–$2.35, while analysts’ consensus rating is "Reduce" with a $1.00 target.
Equillium, Inc. (NASDAQ:EQ - Get Free Report) COO Christine Zedelmayer sold 185,937 shares of the business's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $1.76, for a total transaction of $327,249.12. Following the completion of the sale, the chief operating officer directly owned 191,444 shares of the company's stock, valued at approximately $336,941.44. This trade represents a 49.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Christine Zedelmayer also recently made the following trade(s):
- On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The stock was sold at an average price of $1.50, for a total value of $150,000.00.
- On Monday, December 15th, Christine Zedelmayer sold 11,900 shares of Equillium stock. The stock was sold at an average price of $1.31, for a total value of $15,589.00.
- On Friday, December 12th, Christine Zedelmayer sold 23,804 shares of Equillium stock. The shares were sold at an average price of $1.34, for a total value of $31,897.36.
- On Tuesday, November 25th, Christine Zedelmayer sold 8,098 shares of Equillium stock. The shares were sold at an average price of $0.95, for a total value of $7,693.10.
Equillium Stock Up 6.3%
EQ opened at $1.85 on Tuesday. The firm has a market cap of $112.65 million, a price-to-earnings ratio of -2.98 and a beta of 1.87. Equillium, Inc. has a 52 week low of $0.27 and a 52 week high of $2.35. The business's 50 day moving average is $1.40 and its two-hundred day moving average is $1.35.
Analyst Ratings Changes
EQ has been the subject of several research reports. Wall Street Zen upgraded shares of Equillium from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Equillium in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus target price of $1.00.
Get Our Latest Analysis on Equillium
Institutional Investors Weigh In On Equillium
A number of hedge funds have recently added to or reduced their stakes in EQ. ADAR1 Capital Management LLC increased its position in Equillium by 0.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company's stock worth $8,693,000 after purchasing an additional 48,090 shares during the period. Janus Henderson Group PLC acquired a new position in Equillium during the fourth quarter worth $9,057,000. Balyasny Asset Management L.P. raised its position in Equillium by 3.6% in the fourth quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company's stock worth $3,218,000 after acquiring an additional 72,602 shares in the last quarter. Cantor Fitzgerald L. P. raised its position in Equillium by 32.4% in the fourth quarter. Cantor Fitzgerald L. P. now owns 562,643 shares of the company's stock worth $872,000 after acquiring an additional 137,643 shares in the last quarter. Finally, Diadema Partners LP lifted its holdings in Equillium by 15.8% in the fourth quarter. Diadema Partners LP now owns 347,393 shares of the company's stock valued at $538,000 after acquiring an additional 47,393 shares during the period. Institutional investors and hedge funds own 27.05% of the company's stock.
About Equillium
(
Get Free Report)
Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.
Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
